Items Tagged ‘Stages I-III Pancreatic Cancer’

August 17th, 2016

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving

By

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led by researchers from NYU Langone Medical Center, the Dana Farber Cancer Institute […]

View full entry

Tags: autophagy, fuel, HCQ, News, Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer, stellate cells, study, tumors


June 24th, 2015

“Boosted” Radiation Dose May Make Some Pancreatic Cancers Resectable

By

Because of its location, cancers on the pancreas may invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult and sometimes impossible. Researchers at Fox Chase Cancer Center have identified a way to safely […]

View full entry

Tags: neoadjuvant therapy, News, non-metastatic, Pancreatic Cancer, radiation, Stages I-III Pancreatic Cancer


June 2nd, 2014

Jakafi Plus Capecitabine Improves Survival in Metastatic Pancreatic Cancer Patients with Local and Systemic Inflammation

By

In a study presented at the 2014 ASCO meeting and published in the Journal of Clinical Oncology, researchers reported that treatment with Jakafi® (ruxolitinib) plus capecitabine improved overall survival and progression-free survival in metastatic pancreatic cancer patients with local and systemic inflammation (INFL). INFL is a common marker of cancer that is associated with adverse prognoses […]

View full entry

Tags: jakafi, News, Pancreatic Cancer, ruxolitinib, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


May 23rd, 2014

Radioimmunotherapy and Gemcitabine Combination Shows Extended Survival Times for Metastatic Pancreatic Ductal Cancer Patients

By

In a recent study presented at the American Association for Cancer Research conference on Pancreatic Cancer: Innovation in Research and Treatment, researchers reported that a combination therapy of gemcitabine and radioimmunotherapy (fractionated doses of (90Y-clivatuzumab tetraxetan) given to metastatic pancreatic ductal cancer patients improved survival times over patients who received only radioimmunotherapy. The study was […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


June 2nd, 2011

Sutent Approved for Pancreatic Neuroendocrine Tumors (PNET)

By

The US Food and Drug Administration has approved the targeted drug Sutent® (sunitinib) for the treatment pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are an uncommon type of cancer that develops in the hormone-producing cells of the pancreas. Sutent—which is taken orally—inhibits multiple biologic pathways involved in the growth, replication, and spread of cancer cells. […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


May 10th, 2011

Afinitor Approved for Pancreatic Neuroendocrine Tumors

By

The US Food and Drug Administration has approved Afinitor® (everolimus) for the treatment of advanced pancreatic neuroendocrine tumors (PNET). Pancreatic neuroendocrine tumors are a relatively uncommon type of cancer that develops in the hormone-producing cells of the pancreas. Afinitor is an oral targeted therapy that works by inhibiting a protein known as the mammalian target […]

View full entry

Tags: Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


April 1st, 2011

New Approach to Immune Therapy Shows Promise against Pancreatic Cancer

By

An investigational type of immune therapy that attacks the tissue around a tumor has shown promise in a small study of patients with advanced pancreatic cancer. These results were published in the journal Science. Immune therapies stimulate the body’s immune system to fight cancer. Traditional approaches to immune therapy have targeted the cancer directly, but […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer


February 23rd, 2011

Addition of Axitinib Fails to Improve Pancreatic Cancer Outcomes

By

Among patients with advanced pancreatic cancer, treatment with a combination of Gemzar® (gemcitabine) and the investigational drug axitinib did not result in better outcomes than treatment with Gemzar alone. The results of this Phase III clinical trial were published in Lancet Oncology. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately […]

View full entry

Tags: News, Pancreatic Cancer, Stage IV Pancreatic Cancer, Stages I-III Pancreatic Cancer